PMV Pharmaceuticals (NASDAQ:PMVP) Hits New 1-Year Low at $17.25

Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $17.25 and last traded at $17.31, with a volume of 851 shares changing hands. The stock had previously closed at $17.52.

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group raised shares of PMV Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the company from $35.00 to $43.00 in a report on Wednesday, September 22nd. HC Wainwright reissued a “buy” rating and issued a $62.00 price target on shares of PMV Pharmaceuticals in a report on Monday, November 15th. Finally, Zacks Investment Research raised shares of PMV Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 18th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, PMV Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $48.25.

The stock has a market capitalization of $798.69 million, a P/E ratio of 6.64 and a beta of 0.95. The company’s fifty day simple moving average is $22.69 and its two-hundred day simple moving average is $27.93.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings results on Friday, November 12th. The company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). On average, equities research analysts predict that PMV Pharmaceuticals, Inc. will post -1.23 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in PMVP. OLD Mission Capital LLC bought a new position in shares of PMV Pharmaceuticals during the third quarter worth approximately $1,835,000. Envestnet Asset Management Inc. bought a new position in shares of PMV Pharmaceuticals during the second quarter worth approximately $269,000. Rhumbline Advisers increased its holdings in shares of PMV Pharmaceuticals by 68.0% during the second quarter. Rhumbline Advisers now owns 23,554 shares of the company’s stock worth $805,000 after purchasing an additional 9,536 shares during the period. Swiss National Bank acquired a new stake in shares of PMV Pharmaceuticals during the 2nd quarter worth approximately $844,000. Finally, Rafferty Asset Management LLC boosted its position in shares of PMV Pharmaceuticals by 31.1% during the 2nd quarter. Rafferty Asset Management LLC now owns 34,714 shares of the company’s stock worth $1,186,000 after acquiring an additional 8,242 shares in the last quarter. 96.24% of the stock is currently owned by institutional investors.

PMV Pharmaceuticals Company Profile (NASDAQ:PMVP)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function.

Further Reading: Dividend Kings

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.